Replies to post #6887 on Ariad Pharmaceuticals Inc fka ARIA

[DonShimoda]

yosarian, several companies are running FGFR inhibitor trials including Novartis and AstraZeneca. The FGFR pathway has show to be active in a number of cancer types, including breast cancer, melanomas, pancreatic, prostate, ovarian, gastric and colorectal cancers.See http://www.nature.com/onc/journal/v23/n20/full/1207331a.html

More recently, FGFR has shown to be a possible target for lung cancer ( See http://pharmastrategyblog.com/2010/12/fgfr-as-a-target-in-lung-cancer.html/ )

In the short run, I don't see the FGFR news having much of an impact on Ariad's share price, however, I do think it serves to confirm the value of Ariad's pipeline/drug discovery capabilities in general and the value of ponatinib, in particularly. The fact that Ariad continues to own 100% of ponatinib only makes Ariad that much more attractive to any potential partner/acquirer down the road.

...Don